The most common genetic mutation suitable for targeted therapy within the MAPK pathway, is located in the B-Raf proto-oncogene, serine/threonine kinase (BRAF) accounting for approximately 40–60% of all melanomas [6,7]. This evidence concerns the gene BRAF and melanoma.